Baricitinib mejora aún más los efectos modificadores de la enfermedad a través del desacoplamiento de la asociación entre la actividad de la enfermedad y progresión del daño estructural en pacientes con artritis reumatoide
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221323
Baricitinib reduces structural damage progression versus placebo with background MTX and/or MTX, even in patients with moderate or high disease activity.In patients with RA, TNFi, IL-6i and rituximab have been shown to uncouple the link between disease activity and radiographic progression such that patients are protected from structural damage progression even if remission/low disease activity is not achieved.As such, Lopez-Romero, et al. aimed to evaluate if baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and structural damage progression in patients with RA.
